EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring the binding kinetics of intracellular allosteric antagonists for CC chemokine receptor 2 — a key to improve insurmountable antagonism

Yao Yao, Lisa S den Hollander, Bente Bleijs, Thomas Hartung, Uwe Grether, Natalia V Ortiz Zacarías, Laura H Heitman

Biochemical Pharmacology · 2026

DOI: 10.1016/j.bcp.2026.117864 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Yao Yao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University, the Netherlands. Hauptthemen laut MEDLINE: Receptors, CCR2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Oncode Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CC chemokine receptor 2 (CCR2), a class A G protein-coupled receptor (GPCR), represents a promising therapeutic target for inflammatory and autoimmune diseases. Although several CCR2 antagonists have advanced to clinical trials, none have reached the market, largely due to limited efficacy. In recent decades, binding kinetics has emerged as a key consideration in early drug discovery, complementing traditional equilibrium parameters to enhance clinical efficacy. In parallel, targeting allosteric sites offers unique advantages, i.e. insurmountablility, further improving therapeutic safety and efficacy. However, the interplay between binding kinetics and allosterism has received little attention in drug discovery as a strategy to optimize insurmountablility. As such, we developed a kinetic competition association assay, employing the intracellular allosteric radioligand [3H]LUF7482, which displayed high affinity in both equilibrium and kinetic binding assays, with consistent nanomolar KD values. After validation of the kinetic assay with unlabeled LUF7482, we profiled five known intracellular CCR2 antagonists, including the covalent binder LUF7834 as a positive control, which displayed an apparent long residence time (RT) of 576 min. Functional cAMP assays further revealed a strong correlation between binding kinetics and the extent of insurmountable antagonism. Together, this study established the competition association assay as a robust approach to characterize the kinetic profiles of intracellular CCR2 antagonists, and revealed a clear correlation between binding kinetics and insurmountability. These findings may guide the selection and optimization of next-generation allosteric antagonists targeting CCR2, or the other GPCRs, in drug discovery pipelines, with the aim of improving insurmountability and, consequently, clinical efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CCR2HumansAllosteric RegulationKineticsAnimalsHEK293 CellsProtein BindingAllosteric SiteCricetulusBinding, CompetitiveCHO Cells

Stichwörter der Autor:innen

Binding kineticsCCR2Competition association assayInsurmountabilityIntracellular allosteric antagonistsResidence time

Substanzen

Receptors, CCR2CCR2 protein, human

Autor:innen und Institutionen

  • Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University, the Netherlands.
  • Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University, the Netherlands; Oncode Institute, Leiden, the Netherlands.
  • Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University, the Netherlands; Oncode Institute, Leiden, the Netherlands. Electronic address: l.h.heitman@lacdr.leidenuniv.nl.

Förderung

  • Oncode Institute

Zitieren

APA

Yao, Y., den Hollander, L. S., Bleijs, B., Hartung, T., Grether, U., Ortiz Zacarías, N. V., & Heitman, L. H. (2026). Exploring the binding kinetics of intracellular allosteric antagonists for CC chemokine receptor 2 — a key to improve insurmountable antagonism. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.117864

Vancouver

Yao Y, den Hollander LS, Bleijs B, Hartung T, Grether U, Ortiz Zacarías NV, et al. Exploring the binding kinetics of intracellular allosteric antagonists for CC chemokine receptor 2 — a key to improve insurmountable antagonism. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.117864

BibTeX
@article{Yao2026,
  author = {Yao, Yao and den Hollander, Lisa S and Bleijs, Bente and Hartung, Thomas and Grether, Uwe and Ortiz Zacarías, Natalia V and Heitman, Laura H},
  title = {Exploring the binding kinetics of intracellular allosteric antagonists for CC chemokine receptor 2 — a key to improve insurmountable antagonism},
  journal = {Biochemical Pharmacology},
  year = {2026},
  doi = {10.1016/j.bcp.2026.117864}
}
Kostenlos starten →